SIGLEC10 Specific Neutra™ Antibody Products

SIGLEC10 (Sialic acid-binding Ig-like lectin 10) is a member of the sialic acid binding immunoglobulin superfamily, which is expressed on the surface of cells. There are four tyrosines in the cytoplasmic tail of SIGLEC10, including an immune receptor tyrosine-based inhibitory motif. It is reported to bind to several molecules to participate in the regulation of immune responses, including CD52, CD24, and VAP-1.

Gene ID: 89790, UniProtKB ID: Q96LC7, and OMIM ID: 606091.

Creative Biolabs offers many different anti-SIGLEC10 antibody products. These antibodies are recombinantly expressed and could be used for various purposes. Customization of SIGLEC10-based bispecific antibodies is also available for you here.

Interaction of SIGLEC10

On innate immune cells, SIGLEC10 can bind to the co-stimulatory molecule CD24, which causes anti-phagocytic signaling cascades mediated by SHP-1 and/or SHP-2 phosphatases, thereby inhibiting inflammation mediated by TLR and the cytoskeletal rearrangement required for cellular engulfment by macrophages, as well as promoting the immune evasion of cancer cells. The CD24-SIGLEC-10 interaction also regulates inflammation activated by cancer pathogenesis and danger-associated molecular patterns (DAMPs).

Fig.1 Schematic of CD24-SIGLEC10 signaling in cancer immunotherapy.¹

Besides, SIGLEC10 is also a ligand of CD52, a GPI-anchored glycoprotein. The interaction between SIGLEC10 and CD52 contributes to a decrease in phosphorylation of the T cell receptor-associated tyrosine kinases Lck and ZAP-70, thus inhibiting the functions of T cells. It is also revealed that SIGLEC10 binds to VAP-1 through a free NH₂ group of an arginine side chain and serves as a substrate for VAP-1, associated with lymphocyte adhesion to endothelium and regulation of the inflammatory microenvironment.

Fig.2 Overview of inhibitory mechanisms of the SIGLEC⁺ immune cells in the tumor microenviroment.²

SIGLEC10 as a Target for Antibody in Cancer Immunotherapy

SIGLEC10 is identified as an inhibitory receptor, participating in immune cell activation by its immunoreceptor tyrosine-based inhibitory motifs and regulating immunosuppression through multiple ligands. These findings make it a potential therapeutic target in cancer to strengthen anti-tumor immunity in solid tumors.

It is reported that blocking SIGLEC10 with a monoclonal antibody (mAb) can stimulate proinflammatory responses and suppress tumor growth in vivo by modulating myeloid cell function, which has been proved in an MC38 syngeneic colon adenocarcinoma mouse model. In addition, targeting CD24/Siglec-10 signal pathway has also attracted much attention, and many related preclinical and clinical trials are being conducted.

REFERENCES

1. Gu, Yuanyuan, et al. "The biological roles of CD24 in ovarian cancer: Old story, but new tales." Frontiers in Immunology 14 (2023): 1183285.
2. Lim, Jackwee, Duygu Sari-Ak, and Tanaya Bagga. "Siglecs as therapeutic targets in cancer." Biology 10.11 (2021): 1178.